Drug Shortage Report for LORAZEPAM INJECTION USP

Last updated on 2022-09-22 History
Report ID 156638
Drug Identification Number 02243278
Brand name LORAZEPAM INJECTION USP
Common or Proper name LORAZEPAM
Company Name SANDOZ CANADA INCORPORATED
Market Status MARKETED
Active Ingredient(s) LORAZEPAM
Strength(s) 4MG
Dosage form(s) SOLUTION LIQUID
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 1ML 10LIVI
ATC code N05BA
ATC description ANXIOLYTICS
Reason for shortage Demand increase for the drug.
Anticipated start date 2022-09-19
Actual start date 2022-09-19
Estimated end date 2022-11-25
Actual end date
Shortage status Actual shortage
Updated date 2022-09-22
Company comments Product is available on allocation at wholesalers, based on 75% of historical volumes.
Health Canada comments
Tier 3 Status Yes
Contact Address 110 RUE DE LAUZON
BOUCHERVILLE, QUEBEC
CANADA J4B 1E6
Company contact information 1 800-361-3062

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2022-03-14 English Compare
v2 2022-03-14 French Compare
v3 2022-03-14 English Compare
v4 2022-03-14 French Compare
v5 2022-04-06 English Compare
v6 2022-04-06 French Compare
v7 2022-04-06 English Compare
v8 2022-04-06 English Compare
v9 2022-04-06 English Compare
v10 2022-04-06 French Compare
v11 2022-07-29 English Compare
v12 2022-07-29 English Compare
v13 2022-07-29 French Compare
v14 2022-07-29 English Compare
v15 2022-07-29 English Compare
v16 2022-07-29 French Compare
v17 2022-07-29 English Compare
v18 2022-07-29 French Compare
v19 2022-07-29 English Compare
v20 2022-07-29 French Compare

Showing 1 to 20 of 33